Georgia Bio Quarterly Meeting: State of the Industry Report

April 17, 2019 | 7:30 – 9:00AM
 Upstairs Atlanta, 525 Bishop St NW, Atlanta, GA 30318

Join Georgia Bio for a preview of the 2019 Georgia Life Sciences Industry Analysis. This breakfast meeting will provide members, non-members and Georgia community leaders with valuable industry information.

The state of the industry report, supported by funding from the Biotechnology Innovation Organization (BIO), Georgia Department of Economic Development, Georgia Global Health Alliance, Georgia Research Alliance, Johnson & Johnson, PhRMA, UCB, Inc. and VWR, part of Avantor, features employment and economic contribution from Georgia’s life sciences industry. Georgia Bio CEO Maria Thacker-Goethe will deliver a summary and highlights from the report followed by a panel discussion featuring Georgia Lt. Governor Geoff Duncan, Georgia Research Alliance President & CEO Russell Allen and Head of U.S. Gov’t Relations for UCB Joseph Zorzoli.

“While we don’t want to let the cat out of the bag, it can suffice to say Georgia’s life science industry has shown strong growth compared to the national average and other industry sectors in the state,” Thacker-Goethe said. “We look forward to sharing the report and hosting a lively discussion with our distinguished panelists.”

Georgia Bio has long been a go-to source for data on the bioscience industry in our State. Do not miss this chance to network with industry leaders and learn about one of Georgia’s most innovative sectors. The full 2019 Georgia Life Sciences State of the Industry Report will be made public in the coming weeks.

Those unable to attend can live stream the event on Georgia Bio’s Youtube channel.

Georgia’s Life Sciences Momentum is Getting Noticed Nationally.

August 21, 2026
Genetic Engineering & Biotechnology News (GEN) has named Georgia #4 among its “Next 5 States” for emerging U.S. biopharma clusters . The article highlights UCB’s planned $2 billion investment at in Gwinnett County, Micron Biomedical’s new Alpharetta facility, Manus Bio’s expansion in Augusta, Science Square, Emory University, the CDC — and Georgia Life Sciences’ 10-year Life Sciences Roadmap . This recognition is exciting. But even more importantly, it validates the work happening across our entire ecosystem — and perfect momentum as we head into the 2026 Georgia Life Sciences Summit next week. Read more by visiting: Next 10 U.S. Biopharma Clusters

BIO Supports PDUFA VIII Commitment Letter and Urges Timely Reauthorization

August 17, 2026
Biotechnology Innovation Organization (BIO) Senior Vice President of Science & Regulatory Affairs Annetta Beauregard issued the following statement on the release of the Prescription Drug User Fee Act (PDUFA) VIII commitment letter: “For more than 30 years, PDUFA has helped deliver hundreds of new medicines to American patients. As a lead industry negotiator for the PDUFA VIII agreement, BIO supports the PDUFA VIII commitment letter and its strengthening of regulatory review, advancing innovation, and helping deliver safe and effective treatments to patients. “Specifically, the PDUFA VIII agreement includes important commitments that bolster the FDA’s core review activities, ensure accountability for predictable performance, improve financial sustainability and improve communication, transparency and efficiency. “Timely, bipartisan reauthorization of PDUFA is vital for protecting the health of Americans, strengthening U.S. competitiveness, and maintaining America’s global leadership in medical innovation. BIO is committed to working with Congress to ensure reauthorization by September 30, 2027.” The FDA has announced plans to hold a hybrid public meeting at 9am on 9/16 to discuss the proposed enhancements for the reauthorization of PDUFA for fiscal years (FYs) 2028 through 2033. Learn More about PDUFA and the PDUFA VIII commitment letter HERE .

Georgia Life Sciences Submits Comments on Medicare Drug Price Negotiation Program

August 17, 2026
Representing Georgia’s life sciences community, GLS emphasized the importance of advancing policies that improve affordability and patient access while preserving the environment necessary for continued biomedical innovation. In its comments, GLS urged CMS to maintain a framework grounded in FDA regulatory determinations and raised concerns about how certain proposed policies could affect post-approval research and development, investment in new indications, and patient access to innovative therapies. GLS also encouraged CMS to consider the broader implications for healthcare delivery, including the potential impact on patients and providers in rural and underserved communities. As federal drug pricing policy continues to evolve, Georgia Life Sciences will continue to advocate for approaches that balance affordability, access, and innovation while ensuring Georgia’s life sciences community has a voice in the policymaking process. Read Georgia Life Sciences’ full comments to CMS ( click here ).
MORE POSTS